Allergen-specific immunotherapy: an update on immunological mechanisms of action

Submitted: February 15, 2016
Accepted: February 15, 2016
Published: February 15, 2016
Abstract Views: 710
PDF: 468
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Specific immunotherapy (SIT) is the only treatment able to modify the natural history of the allergic subjects. Several aspects of the immunopathological response modified by SIT have been investigated; the first parameter historically studied was the production of allergen-specific antibodies. An increase of allergen-specific IgG4 and a decrease of IgE appear after SIT. A shift from Th2-polarized immune response toward Th1-oriented pattern has been reported after SIT. More recently, a crucial role for a subpopulation of T cells has been evidenced: T regulatory cells (Treg). Allergic patients have a defect of Tregs. SIT is able of inducing a specific Treg response. Sublingual immunotherapy is an alternative route of administration for SIT. Recent evidence shows that SLIT is also able of inducing a Treg response as detected by IL- 10 production.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Ciprandi, G., G.L. Marseglia, and M.A. Tosca. 2016. “Allergen-Specific Immunotherapy: An Update on Immunological Mechanisms of Action”. Monaldi Archives for Chest Disease 65 (1). https://doi.org/10.4081/monaldi.2006.583.